Torrent Pharmaceuticals

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group. Based in the Indian city of Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Limited
TypePublic
BSE: 500420
IndustryPharmaceuticals
Founded1959 (1959)
FoundersU. N. Mehta
HeadquartersAhmedabad, India
Key people
Sudhir Mehta, Samir Mehta
Products
Revenue ₹8,060 crore (US$1.1 billion) (2020)[1]
₹1,637 crore (US$230 million) (2020)[1]
₹1,024 crore (US$140 million) (2020)[1]
Total assets ₹14,037 crore (US$2.0 billion) (2020)[1]
Total equity ₹4,738 crore (US$660 million) (2020)[1]
Number of employees
12,881 (2020)[1]
ParentTorrent Group
Websitewww.torrentpharma.com

Torrent Pharmaceuticals operates in more than 40 countries with over 2000 product registrations globally. Torrent Pharma is active in the therapeutic areas of Cardiovascular (CV), central nervous system (CNS), gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Drug firm Torrent Pharmaceuticals on 23 July 2019 reported a 32.51 percent rise in its consolidated net profit to Rs 216 crore for the quarter ended 30 June, mainly on account of robust sales in most geographies.[2]

Subsidiaries

It has 7 fully owned subsidiaries:

  1. Heumann Pharma GmbH & Co Generica KG, Germany
  2. Torrent Pharma GmbH, Germany
  3. Torrent do Brasil Ltda., Brazil
  4. ZAO Torrent Pharma, Russia
  5. Torrent Pharma Inc., United States
  6. Torrent Pharma Philippines Inc., Philippines
  7. Torrent Pharma Canada Inc., Canada
  8. Torrent Pharma UK United Kingdom

Torrent Pharmaceuticals acquired Heumann GmbH, a Pfizer company, in 2005.

Operations

The company's key areas are Formulations, API, Drug Discovery, Marketing and Sales of Drugs. Its operations locations are:

Recalls

In 2018, Torrent Pharmaceuticals recalled tablets containing valsartan[5][6] and losartan[7] due to the detection of N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) respectively which are probable human carcinogens.

In September 2019, the FDA issued notice of a sixth product recall of losartan by Torrent Pharmaceuticals when certain batches of losartan contained the contaminant, N-methylnitrosobutyric acid (NMBA), above acceptable daily intake levels determined by the FDA.[8]

References
  1. "Torrent Pharmaceuticals Ltd. Financial Statements". moneycontrol.com.
  2. "Torrent Pharma Q1 net profit up 33 percent to Rs 216 crore". Medical Dialogues. 23 July 2019.
  3. Sunkara, Keshav (19 January 2018). "Torrent Pharma acquires US-based Bio-Pharm". VCCIRCLE. Retrieved 20 July 2019.
  4. PTI (18 March 2016). "Torrent Pharma gets establishment nod from USFDA". The Economic Times. Retrieved 20 July 2019.
  5. "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets". 2018. Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
  6. "FDA updates on valsartan recalls". 2018.
  7. "Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP". 2018. Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
  8. "Updated: Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium / Hydrochlorothiazide Tablets, USP". US Food and Drug Administration. 23 September 2019. Retrieved 23 September 2019.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.